

		E PATENT AND TRADEMARK OFFICE	l.					
TRANSMITTAL LETTER TO THE UNITED STATES			036481-0157					
	DESIGNATED/ELECT	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/507,928						
CONCERNING A FILING UNDER 35 U.S.C. 371								
		PRIORITY DATE CLAIMED 3/19/2002						
TITLE OF INVENTION 3/19/2003 3/19/2002								
IMIDAZOQUINOLINEAMINES AS ADJUVANTS IN HIV DNA VACCINATION								
Ralph Patrick BRAUN et al.								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
\boxtimes	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.							
	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.							
	The US has been elected (Article 31).							
	A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
	is attached hereto (required only if not communicated by the International Bureau).							
	has been communicated by the International Bureau.							
	is not required, as the application was filed in the United States Receiving Office (RO/US)							
	11 (// //							
		emitted under 35 U.S.C. 154(d)(4).						
П								
_	are attached hereto (required only if not transmitted by the International Bureau).							
	have been communicated by the International Bureau.							
П	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
	An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35)							
	U.S.C. 371(c)(5)).							
s 11 to 2	0 below concern other documen	nt(s) or information included:						
	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
\boxtimes	A preliminary amendment (3 pages).							
	An Application Data Sheet under 37 CFR 1.76.							
	A substitute specification.							
	A power of attorney and/or change of address letter.							
\boxtimes	A substitute computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825							
	A second copy of the published international application under 35 U.S.C. 154(d)(4).							
	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							
\boxtimes	Other items or information: Statement Regarding Submission of Sequence Listing (1 p.); Substitute paper copy of sequence listing (20 pages).							
	RNATICT/GB(E OF INMIDAZ) LICANT (alph Paicant here) State of the control of the	DESIGNATED/ELECTICONCERNING A FILINGENATIONAL APPLICATION NO. CT/GB03/01213 E OF INVENTION MIDAZOQUINOLINEAMINES AS ADDICANT(S) FOR DO/EO/US (alph Patrick BRAUN et al.) ceant herewith submits to the United State This is a FIRST submission of this is a SECOND or SUBSECTION of SUBSECTION (9) and (21) indicated below (6), (9) and (21) indicated below (6), (9) and (21) indicated below (1) is attached hereto (required) has been communicated is not required, as the approximate of the united state of the un	DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 RNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE 3/19/2003 E OF INVENTION MIDAZOQUINOLINEAMINES AS ADJUVANTS IN HIV DNA VACCINATION LICANT(S) FOR DO/EO/US alph Patrick BRAUN et al. Cant herewith submits to the United States Designated/Elected Office (DO/EO/US) the facts are reverted to the submits of the United States Designated/Elected Office (DO/EO/US) the facts are reverted to the submits of the United States Designated/Elected Office (DO/EO/US) the facts are reverted to the submits of the United States Designated/Elected Office (DO/EO/US) the facts are reversed to begin national examination procedures (35 U.S.C. 371 (6), 9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(e)(2)) is attached hereto (required only if not communicated by the Internation has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiv An English language translation of the International Application as filed (35 U.S.C. 154(d)(4). Amendments to the claims of the International Application as filed (35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article are attached hereto (required only if not transmitted by the International have been communicated by the International Bureau. have not been made; however, the time limit for making such amendmentave been communicated by the International Bureau. An English language translation of the amendments to the claims under PCT Article are attached hereto frequired only if not transmitted by the International Preliminary U.S.C. 371(c)(5)). S11 to 20 below concern other document(s) or information included: An English language translation of the amendments to the claims under PCT Article are attached to the made and will not be made. An English language translation of the amendments to the claims under PCT Article are attach					

O. (If known, see 37 C.F.R. 1.50 10/507.928	INTER	RNATIONAL APPLICATION NO. PCT/GB03/01213		ATTORNEY 03648		ET NUMBER	
21. The following for	ees are submitted:	1 01/ 02/03/01/21/2		00010		CULATIONS	PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO							0.121
	,	pared by the EPO or JPO		1,080.00			
International prelim USPTO but Internat	inary examination for ional Search Report	te (37 CFR 1.482) not page to prepared by the EPO or	id to JPO	\$920.00			
No international preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO							
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)							
	International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)\$100.00						
		E BASIC FEE AM			\$	920.00	
_	_	th or declaration later that	in 30 months		\$	130.00	
from the earliest claim							
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		\$		
Total Claims	26 - 20 =	6	x \$	18.00	\$	108.00	
Independent Claims	4 - 3 =	1	x \$	86.00	\$	86.00	
MULTIPLE DEPEND	DENT CLAIM(S) (in		+ \$	290.00	\$	0.00	
		TOTAL OF ABOVE		TIONS =	\$	1244.00	
	ms small entity statue are reduced by ½.	is. See 37 CFR 1.27. The		+	\$	0.00	
			SUBT	OTAL =	\$	1244.00	
Processing fee of 130.0 from the earliest claim	_	e English translation later CFR 1.492(f)).	than 30 mon	ths	\$		
		TOTAL	NATIONA	L FEE =	\$	1244.00	
-	_	(37 CFR 1.21(h)). The a	_		\$		
accompanied by an app	propriate cover snee	et (37 CFR 3.28, 3.31). 4			\$	1244.00	
TOTAL FEES PREVIOUSLY PAID =							
2.00		TOTAL I	FEES ENCL	OSED =	\$	0.00	
					Aı	mount to be refunded:	
l						charged:	
a. A check in t	the amount of \$0.00	to cover the above fees i	s enclosed.				
	Please charge my Deposit Account No. <u>19-0741</u> in the amount of <u>\$0.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.						
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0741. A duplicate copy of this sheet is enclosed.						
		card. WARNING: Info					
_		uit under 37 CFR 1.494 ed to restore the applica			-	petition to reviv	re (37 CFR
SEND ALL CORRES	PONDENCE TO:		_	Kah	nd	"Cold	
.	1		;	SIGNATU	RE	•	
Foley & Lardner LLP Customer Number: 22428 NAME							
IVAME							
				35,792	. =====================================		
			1	REGISTR	ATION	NUMBER	





United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. DOX 1450

Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Vinginia 22313-1450
www.usplu.gov

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

10/507,928

Ralph Patrick Braun

036481-0157

INTERNATIONAL APPLICATION NO.

PCT/GB03/01213

I.A. FILING DATE PRI

PRIORITY DATE

03/19/2003

03/19/2002

22428
FOLEY AND LARDNER
SUITE 500
3000 K STREET NW
WASHINGTON, DC 20007

CONFIRMATION NO. 6804
371 FORMALITIES LETTER
OC000000015569767

Date Mailed: 03/30/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 09/17/2004
- Copy of the International Search Report filed on 09/17/2004
- Copy of IPE Report filed on 09/17/2004
- Preliminary Amendments filed on 09/17/2004
- Information Disclosure Statements filed on 09/17/2004
- Biochemical Sequence Listing filed on 09/17/2004
- U.S. Basic National Fees filed on 09/17/2004
- Priority Documents filed on 09/17/2004

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

• Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

The following items MUST be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
 - **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e),





- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/507,928	PCT/GB03/01213	036481-0157

FORM PCT/DO/EO/905 (371 Formalities Notice)